Enlivex Therapeutics Ltd has a consensus price target of $6 based on the ratings of 1 analysts. The high is $6 issued by HC Wainwright & Co. on June 11, 2024. The low is $6 issued by HC Wainwright & Co. on June 11, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co. on June 11, 2024, April 23, 2024, and April 12, 2024, respectively. With an average price target of $6.67 between HC Wainwright & Co., there's an implied 362.96% upside for Enlivex Therapeutics Ltd from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
06/11/2024 | Buy Now | 316.67% | HC Wainwright & Co. | Raghuram Selvaraju | $7 → $6 | Maintains | Buy | Get Alert |
04/23/2024 | Buy Now | 386.11% | HC Wainwright & Co. | Raghuram Selvaraju | → $7 | Reiterates | Buy → Buy | Get Alert |
04/12/2024 | Buy Now | 386.11% | HC Wainwright & Co. | Raghuram Selvaraju | $12 → $7 | Maintains | Buy | Get Alert |
09/25/2023 | Buy Now | 733.33% | HC Wainwright & Co. | Raghuram Selvaraju | $15 → $12 | Maintains | Buy | Get Alert |
08/01/2023 | Buy Now | 941.67% | HC Wainwright & Co. | Raghuram Selvaraju | → $15 | Reiterates | Buy → Buy | Get Alert |
04/24/2023 | Buy Now | 941.67% | HC Wainwright & Co. | Raghuram Selvaraju | → $15 | Reiterates | → Buy | Get Alert |
04/05/2023 | Buy Now | 941.67% | HC Wainwright & Co. | Raghuram Selvaraju | → $15 | Reiterates | → Buy | Get Alert |
02/24/2023 | Buy Now | 941.67% | HC Wainwright & Co. | Raghuram Selvaraju | → $15 | Reiterates | → Buy | Get Alert |
05/02/2022 | Buy Now | 941.67% | HC Wainwright & Co. | Raghuram Selvaraju | $33 → $15 | Maintains | Buy | Get Alert |
The latest price target for Enlivex Therapeutics (NASDAQ:ENLV) was reported by HC Wainwright & Co. on June 11, 2024. The analyst firm set a price target for $6.00 expecting ENLV to rise to within 12 months (a possible 316.67% upside). 5 analyst firms have reported ratings in the last year.
The latest analyst rating for Enlivex Therapeutics (NASDAQ:ENLV) was provided by HC Wainwright & Co., and Enlivex Therapeutics maintained their buy rating.
There is no last upgrade for Enlivex Therapeutics
There is no last downgrade for Enlivex Therapeutics.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Enlivex Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Enlivex Therapeutics was filed on June 11, 2024 so you should expect the next rating to be made available sometime around June 11, 2025.
While ratings are subjective and will change, the latest Enlivex Therapeutics (ENLV) rating was a maintained with a price target of $7.00 to $6.00. The current price Enlivex Therapeutics (ENLV) is trading at is $1.44, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.